Tuomisto, A., Nørskov, N. P., Sirniö, P., Väyrynen, J. P., Mutt, S. J., Klintrup, K., … Herzig, K.-H. (2019). Serum enterolactone concentrations are low in colon but not in rectal cancer patients. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-47622-6
Serum enterolactone concentrations are low in colon but not in rectal cancer patients
|Author:||Tuomisto, Anne1,2; Nørskov, Natalja P.3; Sirniö, Päivi1,2;|
1Cancer and Translational Medicine Research Unit, Department of Pathology, University of Oulu, Oulu, Finland
2Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland
3Aarhus University, Department of Animal Science, AU-Foulum, Blichers Alle 20, P.O. Box 50, DK-8830, Tjele, Denmark
4Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
5Research Unit of Biomedicine and Biocenter of Oulu, University of Oulu, Oulu, Finland
6Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, Oulu, Finland; Department of Surgery, Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland
7Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland
|Online Access:||PDF Full Text (PDF, 1.1 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2019082024792
|Publish Date:|| 2019-08-20
The dietary lignan metabolite, enterolactone, has been suggested to have anti-cancer functions, and high serum enterolactone concentrations have been associated with decreased risk of breast and prostate cancers. We hypothesized that serum enterolactone concentrations as a marker of plant-based foods are associated with decreased risk in colorectal cancer (CRC). We measured serum enterolactone glucuronide and sulfate concentrations by liquid chromatography-tandem mass spectrometry in 115 CRC patients and 76 sex- and age-matched controls and analyzed the results with respect to tumor parameters, clinical parameters, and systemic inflammatory markers. Patients with colon cancer had significant lower serum enterolactone glucuronide and sulfate concentrations than controls (glucuronide: median 3.14 nM vs. 6.32 nM, P < 0.001; sulfate: median 0.13 nM vs. 0.17 nM, P = 0.002), whereas rectal cancer patients had similar enterolactone levels as controls (glucuronide: median 5.39 nM vs. 6.32 nM, P = 0.357; sulfate: median 0.19 nM vs. 0.17 nM, P = 0.452). High serum enterolactone concentrations were associated with low tumor grade, high serum creatinine levels, and concomitant diabetes. In summary, our results suggest that serum enterolactone concentrations are decreased in colon but not in rectal cancer. Further investigations are required to assess whether this reflects an altered lignan metabolism by the colon microbiome.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was supported by grants from Medical Research Center Oulu and Thelma Mäkikyrö Foundation.
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.